Intervention Protocol

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

  1. Daniel Simancas-Racines1,*,
  2. Arturo J Martí-Carvajal2,
  3. Ricardo Hidalgo1,
  4. Shrikant Bangdiwala3

Editorial Group: Cochrane Injuries Group

Published Online: 14 MAR 2012

DOI: 10.1002/14651858.CD009745


How to Cite

Simancas-Racines D, Martí-Carvajal AJ, Hidalgo R, Bangdiwala S. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD009745. DOI: 10.1002/14651858.CD009745.

Author Information

  1. 1

    Universidad Tecnológica Equinoccial, Facultad de Ciencias de la Salud Eugenio Espejo, Quito, Pichincha, Ecuador

  2. 2

    Universidad de Carabobo and Iberoamerican Cochrane Network, Valencia, Edo. Carabobo, Venezuela

  3. 3

    Collaborative Studies Coordinating Center, Department of Biostatistics, School of Public Health, Chapel Hill, North Carolina, USA

*Daniel Simancas-Racines, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Pichincha, Ecuador. danielsimancas10@gmail.com. srda12291@ute.edu.ec.

Publication History

  1. Publication Status: New
  2. Published Online: 14 MAR 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the clinical effectiveness of leukoreduction of red blood cell concentrates for preventing adverse reactions following allogeneic blood transfusion.